Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy

Area of Science:

• Immunology
• Systems Biology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) like anti-PD-1 antibodies have advanced cancer immunotherapy.
• Treatment efficacy for ICIs varies significantly among patients.
• Emerging evidence points to sex-based biological differences influencing ICI response.

Purpose of the Study:

• To investigate how sex-specific immune system differences contribute to response variability in anti-PD-1 therapy using a systems biology model.
• To explore the efficacy of combination therapy with recombinant IL-12 in a sex-specific context.

Main Methods:

• Developed a systems biology model incorporating sex-specific immunological parameters.
• Simulated treatment responses based on the extended model.
• Analyzed sex-specific differences in response to anti-PD-1 therapy and combination therapy with IL-12.

Main Results:

• Simulation results align with clinical observations, indicating males, on average, show a stronger response to anti-PD-1 treatment than females.
• Identified sex-specific efficacy differences in combination therapy with recombinant IL-12.
• Model successfully integrated sex-specific immunological distinctions.

Conclusions:

• Sex is a critical factor influencing immunotherapy outcomes.
• Personalized immunotherapy strategies accounting for sex-specific immunological profiles are essential for optimizing treatment.
• Findings support the development of tailored cancer treatment plans based on individual biological characteristics.